Thanks for the link.
CHM's AML trial is at MDA Texas and if I recall it correctly the current CHM 1101 ph1b got them as one trial site as well.
And all that plus the other platforms for AUD 5m. The ASX " really got an understanding" of valuing CHM.
The re-rate will come at some stage, fortunately I got the time to wait. One of those rare opportunities to lay a foundation for a huge windfall if the data turn into approved treatments. Not to mention the benefits for cancer sufferers.
GLTA
Ann: Positive in vitro data for CHM 1301 CAR NK cells-supplement, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |